Moderate to Severe Glabellar Lines Clinical Trial
Official title:
A Single Center, Randomized, Double-Blind, Active-controlled, Single-Dose, Phase I/II, Non-Inferiority Study Comparing ATGC-100 and Botox for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects
Phase I/II clinical trial will be integrated and conducted. In phase I clinical trial, subjects with moderate to severe glabellar lines at maximum frown are enrolled and safety is assessed after 12 weeks of administration of 20U of ATGC-100. In phase II clinical trial, subjects with moderate to severe glabellar lines at maximum frown are enrolled, and efficacy and safety are assessed by comparing with Botox (Allergan).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05743634 -
A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT05463965 -
A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT06151561 -
Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
|
Phase 1 | |
| Completed |
NCT02353871 -
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Recruiting |
NCT06199336 -
A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT06354127 -
DWP450 for Treating Moderate to Severe Glabellar Lines
|
Phase 3 |